Skip Navigation LinksHome > September 2013 - Volume 28 - Issue 5 > Open-label pilot study on vitamin D3 supplementation for ant...
International Clinical Psychopharmacology:
doi: 10.1097/YIC.0b013e3283628f98
Original Articles

Open-label pilot study on vitamin D3 supplementation for antipsychotic-associated metabolic anomalies

Thakurathi, Neelama; Stock, Shannonf; Oppenheim, Claire E.a; Borba, Christina P.C.a,b; Vincenzi, Brendaa; Seidman, Larry J.b,c,d,e; Stone, William S.b,c; Henderson, David C.a,b

Collapse Box


Previous studies have linked vitamin D deficiency to hypertension, dyslipidemia, diabetes mellitus, and cardiovascular disease. The aim of this study was to investigate the short-term effects of vitamin D3 supplementation on weight and glucose and lipid metabolism in antipsychotic-treated patients. A total of 19 schizophrenic or schizoaffective patients (BMI>27 kg/m2) taking atypical antipsychotics were recruited and dispensed a 2000 IU daily dose of vitamin D3. On comparing baseline with week 8 (study end) results, we found a statistically significant increase in vitamin D3 and total vitamin D levels but no statistically significant changes in weight, glucose, or lipids measurements. Patients whose vitamin D3 level at week 8 was 30 ng/ml or more achieved a significantly greater decrease in total cholesterol levels compared with those whose week 8 vitamin D3 measurement was less than 30 ng/ml. These results suggest that a randomized trial with a longer follow-up period would be helpful in further evaluating the effects of vitamin D3 on weight, lipid metabolism, and on components of metabolic syndrome in antipsychotic-treated patients.

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.